Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz. - Wikidata - wikimedia - TriplyDB

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.

http://www.wikidata.org/entity/Q35547723

about

Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

P2860

Q26852535-14553AE2-7F5F-4B52-A22F-C7F2C59DF72B Q34531724-4D3A740D-9BB7-457F-90E5-2C0B5FD9E14B Q37358704-07CEE165-ED3A-4827-AB28-F6A640A29899 Q37538760-05B9A74F-1122-4A48-B67C-54562B553A41 Q38755666-6B9CFE92-9F13-45C9-A876-2A6019229465 Q38798449-F9C029EC-D04E-4D2F-A80C-F9CA32DFE6CA Q40694902-20FD6D28-9F0C-4AD2-9866-7316D7582534

P2860

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.

http://www.wikidata.org/entity/Q35547723

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@ast

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@en

type

label

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@ast

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@en

prefLabel

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@ast

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@en

P1433

Q35547723-83AA7460-8915-422C-B9F4-16E731979F82

P1476

Q35547723-D7119C21-541D-49DF-A452-3986AC07002E

P2093

Q35547723-54E74F5C-32D6-4812-87EA-1099ED025ACB

Q35547723-B3EE14AA-9560-4686-9173-AFB9B49F4010

Q35547723-B699AD8C-F640-46A9-98FB-8A6D331A0CC2

Q35547723-CD6462E1-3467-4004-9E86-D4BDB9CC4E11

Q35547723-CDB2214A-CC7A-4ED1-8830-1A0D7D6C6A35

Q35547723-EB7D048B-8DAF-428C-A965-ACDBA12341A3

P2860

Q35547723-0876731C-8B3B-41A7-B566-868B27610E14

Q35547723-08C00858-0C36-4573-93EC-C3F6181540CE

Q35547723-0C6664E2-B89A-477B-927D-6F33B3AD8768

Q35547723-0F50EEAB-014A-4420-A15A-7A9B6018BF72

Q35547723-1537207B-EEAB-49BA-A1AB-259261F3299B

Q35547723-19E2C75E-15F5-450E-A735-9E66B412A4EC

Q35547723-1D0FD4D3-DBCC-41FE-98EF-0EF94EEDD4BE

Q35547723-1E873013-6AB0-4714-A3F2-5BF3C6E60EEF

Q35547723-30035C74-C96B-4B23-9837-F52DC1FA53F3

Q35547723-32082976-4F7D-4134-8EAF-5D72EAC88380

P304

Q35547723-0A39A679-5E2F-40FE-826A-A02E73E5CBD7

P31

Q35547723-1B5682C2-75E1-4490-900E-CB80A9806719

P356

Q35547723-0EB0BFF0-8DA7-4CE9-AE86-7D528D7AF5D0

P407

Q35547723-C53629E2-8884-4434-A436-D3B68826EFE3

P433

Q35547723-C91EC3DC-7342-4375-8FD4-26A0CA074150

P478

Q35547723-33088627-7F2E-45F9-9528-1D9168350AF7

P577

Q35547723-65B6248F-8ACA-4050-B9A4-1F3DFBECAB5D

P698

Q35547723-38F3B6F4-2825-4E44-8BC5-99AF339F7E9C

P921

Q35547723-2B7E95AB-CAE5-42FF-8F31-AD0166653C2D

Q35547723-93FE7A0C-8D89-49A3-830C-B63B2C3DCEE3

Q35547723-B756C5C0-8868-4572-9F80-AA69C966D46A

P932

Q35547723-6EFC35C1-5A1F-4316-ABE4-B5F11F993037

P356

P1433

The Journal of Clinical Pharmacology

P1476

Population pharmacogenetic-bas ...... droxy- and 8-hydroxyefavirenz.

@en

P2093

A M Abdelhady

http://www.w3.org/2001/XMLSchema#string

B R Overholser

http://www.w3.org/2001/XMLSchema#string

C W Yeo

http://www.w3.org/2001/XMLSchema#string

F Jiang

http://www.w3.org/2001/XMLSchema#string

J G Shin

http://www.w3.org/2001/XMLSchema#string

Z Desta

http://www.w3.org/2001/XMLSchema#string

P2860

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.

Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.

P304

87-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.208

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24142869

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

4412845

http://www.w3.org/2001/XMLSchema#string